Amphastar Pharmaceuticals is undergoing a significant strategic pivot from commodity generics to high-barrier proprietary and biosimilar products, targeting 85% of its pipeline in these categories by 2026. While long-term growth drivers like BAQSIMI and Primatene MIST remain robust, near-term performance is heavily pressured by pricing headwinds, competitive dynamics, and rising operational expenses. Q1 2026 results highlighted these challenges, with net income falling sharply to $6.4 million from $25.3 million in the prior-year period despite flat revenues. Given the margin compression and execution risks associated with its complex pipeline, a Hold recommendation is warranted until clear signs of margin stabilization and successful pipeline commercialization emerge.